Yoshihiro Hiramatsu, MD, PhD1, Hirotoshi Kikuchi, MD, PhD1, Amane Hirotsu, MD1, Wataru Soneda, MD1, Tomohiro Murakami, MD1, Tomohiro Matsumoto, MD1, Yusuke Ozaki, MD1, Kinji Kamiya, MD, PhD1, Takanori Sakaguchi, MD, PhD1, Hiroyuki Konno, MD, PhD, FACS2, Hiroya Takeuchi, MD, PhD, FACS1. 1Department of Surgery, Hamamatsu University School of Medicine, 2Hamamatsu University School of Medicine
Background: Robot-assisted surgery using da Vinci Surgical System(DVSS) is thought to have many advantages over conventional laparoscopic surgery. It was reported that the use of the surgical robot might reduce surgery-related complications, then a multi-institutional historically controlled prospective cohort study on the feasibility, safety, effectiveness and economical efficiency of robotic gastrectomy (RG) for resectable gastric cancer was conducted in Japan. This study evaluated the safety of RG using DVSS Xi.
Methods: This single-center, prospective phase II study included patients with resectable gastric cancer (UMIN000019366). The primary endpoint was the incidence of post-operative complications greater than Grade III according to Clavien-Dindo classification during one month after surgery. The secondary endpoints included all adverse events and completion rate of robotic surgery.
Results: From Oct 2015 to Jan 2017, 22 patients were enrolled for this study. The incidence of post-operative complication greater than grade III was 0%. The overall incidence of adverse events was 18.1% (grade I; 13.6%, grade II; 4.5%). No patient required conversion to laparoscopic or open surgery; thus, the RG completion rate was 100%.
Conclusion: This study suggested the introduction of RG using DVSS Xi for gastric cancer seems to be safe and feasible.
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 87746
Program Number: P817
Presentation Session: iPoster Session (Non CME)
Presentation Type: Poster
sages_adbutler_leaderboard